Major study reveals safest way to take Valium and Ativan


More than 60 years after benzodiazepines were introduced, doctors have uncovered the first reliable evidence to confirm the belief that taking these drugs, such as Valium and Ativan, intermittently rather than continuously is associated with fewer side effects and reduced falls, hospitalizations and deaths

Benzodiazepines such as Ativan, Librium and Valium were first used to treat anxiety and insomnia in the early 1960s. By 1977, these were the most prescribed medicines globally; they are still regarded as reasonably safe and effective (although some patients developed tolerance, and became dependent on the drugs, while the risk of falls and fractures remains a concern in older people). They are still very widely used, but modern antidepressants (such as SSRIs) are more commonly prescribed.

Most studies on benzodiazepines (“benzos”) only followed health outcomes for up to six to eight weeks, meaning that there has been little information on the results of long-term use over months and years. This has led to conflicting views among doctors, and some clinicians saying that benzo use should be limited to a few weeks to avoid the risks of tolerance and dependence, or even that they should not be given to people over 65 at all, whereas other doctors advocate long-term use as being acceptable.

A new study is presented at the ECNP Congress in Barcelona, held Oct. 7–10, after recent publication in the Journal of Psychopharmacology. Lead researcher Dr. Simon Davies (of the Center for Addiction and Mental Health, Toronto, ON, Canada) said, “Using a large, dataset from Ontario, Canada, we were able to examine how people over the age of 65 with anxiety or insomnia actually took benzodiazepines after starting them. We were also able to link this with other health outcomes.

“So this meant considering 57,000 people who took benzos regularly on most days over a period of six months (chronic users) and 113,000 matched people who took the medicines over a similar period, but with breaks where they didn’t take benzodiazepines (intermittent users). We then followed both groups for a further year. The results were striking.

“Our results show that changing the way people take benzos from chronic to intermittent could lead, over one year, to 20% fewer hip fractures 33% fewer in men), 7.5% fewer falls requiring hospitalization or emergency visits and a 24% fall in the chance of needing to go into long term care.”

These are not just short-term consequences. Falls are the leading cause of death for people over 65 in the US and Canada. More than 1 in 5 elderly people who sustains a hip fracture dies within a year.

Dr. Davies continued, “This work shows that where possible, patients over the age of 65 with anxiety or insomnia who are taking Ativan, Valium or another benzo long-term would better not to stay on the drugs continuously. In practical terms there will be some who can’t change or do not want to change.

“These results allow you to understand the excess risks of falls, fractures, emergency visits, long term care home admission and death that you are accepting using benzodiazepines chronically rather than intermittently. Of course, these are still prescription drugs, so they need to be taken under the guidance of your clinician.”

Commenting, Professor Christian Vinkers (of Amsterdam University Medical Centers) said, “This is a very important study, confirming once again the long-term benzodiazepine use should not be encouraged. The risk of falls, as well as cognitive side effects and impaired driving skills—with the risk of road accidents—make chronic overuse of benzodiazepines a public health issue. Of course, there is a small group of patients who should have access to long-term use, but it is reasonable to assume that this group is currently too large.”

More information:
Simon JC Davies et al, Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study, Journal of Psychopharmacology (2022). DOI: 10.1177/02698811211069096

Journal information:
Journal of Psychopharmacology

Source: Read Full Article